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The impact of national guidelines on venom immunotherapy practice in
the United Kingdom
L. Diwakar1, P. Ewan2, P. A. J. Huber3, A. Clark2, S. Nasser2 and M. T. Krishna4
1University of Birmingham and University Hospitals Birmingham, Birmingham, 2Allergy clinic, Addenbrookes Hospital, Cambridge, 3BSACI, London and
4Heart of England NHS Foundation Trust and Aston University, Birmingham, UK
Venom immunotherapy (VIT) is the only effective treat-
ment for prevention of further anaphylactic reactions to
bee and wasp stings in allergic individuals. A previous
national survey carried out in 2006/2007 revealed sig-
nificant heterogeneity in UK practice [1]. The British
Society for Allergy and Clinical Immunology (BSACI)
guidelines for the diagnosis and management of hyme-
noptera venom (HV) allergy were subsequently pub-
lished in 2011 [2] (Table 1).
This repeat survey was carried out to assess whether
publication of BSACI guidelines helped improve the
diagnosis and management of HV allergy in the UK
National Health Service (NHS).
Methods
The survey questionnaire (same as in previous survey
[1] with two additional questions, Appendix 1) was
emailed via a web link (www.surveymonkey.com) to all
consultant physicians who were members of the BSACI
in March 2014. A total of 247 practitioners from 80 UK
NHS hospitals were contacted. Respondents were
requested to identify their speciality interest as well as
whether they were adult or paediatric physicians.
Two reminder emails were sent in April/May 2014.
The results were compared with the data obtained
during the 2006/2007 survey to assess the impact of
the BSACI guideline on the practice of HV allergy in
UK NHS allergy services.
Results
A total of 113 (46%) responses were received. One hun-
dred and seven (95%) respondents worked in 75 centres
across the United Kingdom. Two respondents were from
the republic of Ireland and three UK respondents did
not divulge their centre of work. One responder was not
practising in the United Kingdom at the time of the sur-
vey and was therefore excluded from analysis.
Over half of the respondents of this resurvey (n = 67/
113; 59.3%) carried out VIT. Of these, 64 responses
received from 35 UK centres were deemed eligible for
analysis.
Amongst the 64 respondents undertaking VIT, 28 (44%)
were adult or paediatric allergists, 21 (33%) were immu-
nologists and 15 (23%) identified themselves as ‘other’
clinicians. A majority of the latter group (n = 10) were
respiratory physicians with an interest in allergy, whilst
three were paediatricians with an interest in allergy.
Clinic structure
A total of 37 (58%) respondents managed only adults
with allergy, 12 (19%) only treated children, whilst 15
respondents (23%) managed both adults and children at
their clinic.
Six centres had no patients undergoing VIT, whilst
seven had more than 30 patients undergoing VIT at the
time of the survey (see Fig. 1). Just over half the respon-
dents (52%) had 10 or more patients undergoing VIT at
their centre at the time of the survey. Most clinics were
staffed by a specialist nurse (86%) and/or by a consultant
(76%). Some centres (44%) had junior doctors in the clinic.
Diagnosis of HV allergy
The table provided summarizes the clinical practice relat-
ing to the diagnosis of HV allergy. About two-thirds of
the respondents use skin prick tests (SPTs) as the first-line
investigation for diagnosis and a majority carried out
intradermal tests (IDTs; 80%) and/or component-resolved
diagnostic (CRD) tests (85%) when skin prick and serum-
specific IgE tests do not provide a clear diagnosis. Base-
line serum tryptase (bT) measurement is also requested by
most respondents (88%) in all patients presenting with a
systemic reaction to HV, irrespective of severity.
Safety of VIT practice
Almost all respondents check the patients’ identity at
each visit and ensure that changes to medication are
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regularly documented. Only about 65% of respondents
check pulse and blood pressure before every injection.
90% check peak expiratory flow rate (PEFR) prior to
VIT injections. Most (88%) monitor patients for a mini-
mum of an hour post-VIT injection.
Most physicians (92%) consider individuals with
severe, uncontrolled or brittle asthma unsuitable for
VIT. Ongoing beta-blocker and ACE inhibitor therapy
is considered as a contraindication by most (78%
and 62%, respectively), whereas most physicians
(88%) are happy to initiate VIT in patients with an
elevated bT.
The data pertaining to administration of VIT are sum-
marized in the table. The majority prefer conventional
up-dosing protocol (76%) aiming for a maintenance
dose of 100 mcg (98%) and administer maintenance
injections at a 4- to 8-weekly interval (94%).
VIT protocols
Conventional protocol (12-week gradual up-dosing) is
favoured by most (76%), although rush (4–7 days) and
ultra-rush (1–2 days) up-dosing are preferred by 22%.
Forty percent of respondents routinely use pre-medica-
tion with antihistamines in all patients undergoing VIT,
whereas the others only used antihistamines in patients
experiencing allergic reactions to VIT.
Ninety percent offer VIT for 3 years, whereas the
others routinely continue treatment for 5 years.
A third and none of the respondents check serum-
specific IgE and serum-specific IgG4 antibodies to HV,
respectively, at the end of the VIT programme. Five
percent of the respondents extended VIT on the basis of
Table 1. Results of the VIT UK national surveys
2006/2007† (%)
2014 Survey (%)
Overall
n = 48
Overall
n = 64
Allergists
n = 28
Immunologists
n = 21
Other
n = 15
Diagnosis of HV allergy
SPT is the first-line test (%) 45 66 77 65 46
SPT highest concentration is 100 mcg/mL (%) 43 36 46 15 54
SPT highest concentration is 300 mcg/mL (%) 55 62 54 85 36
If sSIgE*and SPT negative, IDT will be performed by (%) 50 80 91 85 54
IDT highest concentration is 1.0 mcg/mL (%) 45 81 74 94 71
Component-resolved tests performed if dual positive for
wasp and bee venom sSIgE and skin tests (%)
NA‡ 87 81 95 77§
Baseline tryptase (bT) checked in all patients with a
history of systemic reaction (%)
47 88 85 100 70
Administration of VIT
Conventional up-dosing protocol preferred (%) 92 74 55 90 82
Ultra-rush/rush induction protocol ever used (%) 25 38 60 21 27
Antihistamines for all VIT patients before injection (%) 42 40 53 22 46
Maximum interval between injections during
maintenance is 4–8 weeks (%)
89 94 90 94 100
Target maintenance dose is 100 mcg/mL (%) 89 98 100 94 100
Patients monitored for at least 1 h post-injection (%) NA‡ 88 90 94 73
Optimal duration of VIT is 3 years (%) 55 83 84 94 64
VIT extended if sSIgE* detected at the end of 3–5 years (%)¶ 14 6 5 5 27
*Serum-specific IgE.
†Results from the 2006/2007 survey.
‡This question did not feature in the previous survey.
§An additional 9% would refer patient to tertiary centre.
¶Not recommended in the BSACI guideline.
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Fig. 1. Number of centres as per VIT patient load.
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a positive serum-specific IgE test to insect venom at the
end of 3 years.
VIT survey results from 2006 to 2007 [1]
In the survey carried out in 2006/2007, 53 responses
were received in response to 86 online questionnaires
(61.6% response rate). Serum-specific IgE was more fre-
quently used as a first-line investigation (55%) com-
pared to SPTs (45%). Only half the respondents carried
out intradermal tests when initial tests were negative.
Fifty-three percent checked bT in individuals with sys-
temic reactions to insect venom. Ninety-two percent
preferred conventional up-dosing protocols for VIT and
56% carried out VIT for 3 years.
Since the last survey, there has been a statistically
significant improvement in the use of skin tests as first
line of diagnosis (P = 0.05, chi-square test, 1 df), in the
use of intradermal tests when skin and specific IgE tests
are not conclusive (P = 0.004, chi-square test, 1 df) and
in testing baseline tryptase levels when an individual
presents with a systemic reaction to insect venom
(P < 0.00001, chi-square test, 1 df).
Discussion
The current survey was sent to practitioners across 80
UK NHS trusts. Responses were received from 72 trusts.
Thus, the data obtained are a credible snapshot of cur-
rent UK NHS practice.
The response rate was moderately good in this sur-
vey. However, response rate was marginally higher in
the 2006/7 survey (62%), although the absolute num-
ber of responses was lower (53 responses). Of the
respondents, 48 (85%) carried out VIT at their centre
[1] as opposed to 59.3% in the current survey. A few
questions were added to the 2006/2007 questionnaire
to reflect developments in the practice of VIT and also
to improve the breadth of data collection. For exam-
ple, data regarding speciality of the respondents or
data related to the use of CRD tests were not collected
in the previous survey.
Although the results of the current survey are not
directly comparable with the results from the 2006/
2007 study [1], the diagnostic practices for HV allergy
in the United Kingdom appear to have improved fol-
lowing publication of the BSACI guidelines [2] (see
Box 1).
Component-resolved diagnosis has become an
invaluable tool enhancing the accuracy of diagnosis,
particularly in patients with dual sensitization to bee
and wasp venoms [3]. It is encouraging to note that a
majority (87%) of the respondents use these tests in
diagnosis of HV allergy as per the guideline
recommendations.
Our data have also highlighted significant deviations
from recommendations made in the BSACI guideline
regarding diagnosis of HV allergy (see Box 2).
Concomitant use of beta-blockers can potentially
interfere with the therapeutic efficacy of adrenaline and
cause refractory or protracted anaphylaxis. The BSACI
guideline therefore recommends that these drugs are
substituted or temporarily withdrawn following a risk–
benefit analysis in the individual patient [2]. A majority
of the respondents were unwilling to offer these
patients VIT at their centre. Use of ACE inhibitors, on
the other hand, is not associated with an increased risk
during VIT, but is a recognized risk factor for anaphy-
laxis to field stings [2]. Nevertheless, it is interesting to
note that over 60% of the respondents would not
initiate VIT in these patients. These data suggest that
individuals at high risk of anaphylaxis are being denied
an effective, long-term treatment for their venom
allergy. A recent position paper from the European
Box 2. Deviations from BSACI guidelines
 One-third do not use SPTs as the primary diag-
nostic tool, and about 20% do not carry out IDT
at their centre when SPT and serum-specific IgE
are negative.
 62% of the respondents use concentrations up to
300 mcg/mL for SPTs and 15% use up to 10 mcg/
mL for IDTs, which are higher than those recom-
mended in the BSACI guideline
 12% of respondents do not check bT in all
patients with a systemic reaction to HV.
 12% do not monitor patients for an hour after
administration of VIT injection.
 35% do not measure pulse and blood pressure
prior to the VIT injection.
 60% of the respondents do not offer VIT to indi-
viduals on ACE inhibitor therapy.
 5% may continue VIT beyond 3 years based on a
positive serum-specific IgE result.
Box 1. Examples of improved practice since last sur-
vey (In keeping with BSACI guidelines)
 There has been a significant increase in the num-
ber of practitioners who carried out SPTs (66% vs.
45% in 2006/2007), IDTs (80% vs. 50% in 2006/
2007) and check bT (88% vs. 47% in 2006/2007)
in keeping with the BSACI guidelines.
 A majority of practitioners offer VIT to patients
with an elevated bT.
© 2016 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd., 46 : 749–753
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Academy of Allergy and Clinical Immunology (EAACI)
concluded that concomitant treatment with a beta-
blocker is not a contraindication for VIT, whereas ACEi
should be substituted with an alternative agent where
feasible[3]. These points should be revisited in the next
iteration of the BSACI guideline.
Although some aspects of VIT have improved in the
United Kingdom, others remain unchanged since our last
survey; a few of these (e.g. not checking bT in patients
with systemic reactions, inadequate monitoring follow-
ing VIT injections) could potentially compromise patient
safety.
Several factors may affect uptake of a guideline.
These include quality of evidence underlying the guid-
ance, extent of promotion and awareness of the guid-
ance and commitment of individual trusts to guideline
implementation [4]. Studies in other areas have sug-
gested that centres with high patient throughput show
better adherence to guidelines [5], although no such
differences were found in our survey. Reduced uptake
in some aspects (such as the use of 100 mcg/mL vs.
300 mcg/mL solutions for SPT, measurement of PEFR
and blood pressure prior to administration of VIT injec-
tion) can be explained in part by conflicting expert
opinions. However, these explanations cannot be
applied to all other aspects of the guidance for which
the uptake was less than satisfactory. Previous explo-
rations regarding effectiveness of guidelines have not
been able to suggest that specific interventions improve
uptake [6, 7]. However, it has been suggested that regu-
lar dissemination of educational material and discussion
in short (e.g. lunchtime) meetings [6], active clinician
engagement using interactive educational sessions and
automated clinical reminders [7] may all be practical
and useful in guideline implementation. Improved dis-
semination can improve equity and provision of high
standards of care, which are the stated objectives of
NHS England Specialised Services.
Strengths and limitations
This is the first report assessing the impact of a
national guideline on allergy services in the published
literature. The British Society for Allergy and Clinical
Immunology is the largest professional body for aller-
gists and clinical immunologists in the United King-
dom. Venom immunotherapy in the United Kingdom
is administered only in secondary care under specialist
supervision. The initial survey was carried out prior to
publication of the BSACI guidelines in 2011. However,
there have since been two other significant
publications that could have affected UK VIT practice.
These include the NIHR HTA guidance for the use of
Pharmalgen in VIT [8] as well as a systematic review
from the Cochrane collaboration highlighting the
effectiveness of VIT in the prevention of allergic reac-
tions to insect stings [9].
The response rate for the current survey was lower
(46%) although the number of respondents was greater
than in the previous survey. Only 59% of those who
responded (27% overall) practised VIT during the recent
survey. It is worth stating that this is comparable to the
response rate of the previous survey (56%) and that of
other national UK allergy surveys [10].
In addition, there was no classification of practition-
ers into the allergy, immunology or other specialist
groups. The results are presented based on the self-
identification of respondents into these categories in
the recent survey questionnaire.
The previous survey was sent only to 81 UK practi-
tioners identified as practising VIT from the BSACI
website. The membership has since grown and database
updated and therefore the current cohort (247 members)
is not directly comparable to those surveyed in 2006/
2007. Respondents chose not to answer some questions
in the survey. Where data were missing, this was
ignored. This approach may have potentially introduced
some bias into the interpretation of the data.
As with any survey, these data are subject to
response bias (i.e. the tendency of respondents to pro-
vide responses considered ‘acceptable’ rather than those
that reflect their true practice). However, it is hoped
that this was minimal given that in our survey, the
respondents were made aware of the confidential nature
of the responses upfront.
The survey may also be subject to a selection bias, as
only those individuals with some familiarity with the
guidelines may have responded to the survey.
Unanswered questions and future research
recommendations
The data from this survey have been used to assess the
uptake of VIT guidelines in the United Kingdom.
Respondents may be directly asked for their opinion
regarding existing guidelines in future surveys. This
would help improve the quality and uptake of future
guidelines.
To understand the effect of centre size on practice,
future surveys could be made centre-focussed rather than
focussing on individual practice where appropriate. Also,
it may be useful to have generic sections in the question-
naire as well as separate sections aimed at adult and pae-
diatric practices since practice of allergy in children can
be different from that of adults in some areas (e.g. use of
intradermal tests, checking blood pressure before injec-
tions, issues around the use of beta-blockers and ACEi).
To assess patient selection criteria in accordance with
the NIHR HTA recommendations [8], future surveys
should include questions about the use of generic [11]
© 2016 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd., 46 : 749–753
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or specific [12] quality of life (QoL) questionnaires
before commencement and after completion of VIT.
Conclusion
Despite above-stated limitations, the current survey
suggests better adherence to best practice parameters in
several domains of diagnosis and management of HV
allergy. However, the data also highlighted the follow-
ing areas where further improvement is needed: use of
SPTs as the first-line investigation, use of optimal aller-
gen concentrations for skin tests, checking bT in all
patients with systemic reactions to HV, and monitoring
patients for an optimal duration following VIT injec-
tions. Updating guidelines regularly and having a plan
for dissemination may improve adherence.
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